World Investment Advisors Buys New Shares in Halozyme Therapeutics, Inc. $HALO

Posted by Francis Steltz on May 19th, 2026

World Investment Advisors bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 10,014 shares of the biopharmaceutical company’s stock, valued at approximately $674,000.

A number of other large investors have also bought and sold shares of the stock. Root Financial Partners LLC purchased a new position in Halozyme Therapeutics during the 3rd quarter valued at about $25,000. Larson Financial Group LLC boosted its holdings in Halozyme Therapeutics by 3,118.2% in the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 343 shares in the last quarter. Clearstead Advisors LLC grew its position in Halozyme Therapeutics by 107.7% during the 3rd quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 265 shares during the last quarter. Penserra Capital Management LLC bought a new stake in shares of Halozyme Therapeutics during the third quarter valued at approximately $52,000. Finally, Wexford Capital LP bought a new position in shares of Halozyme Therapeutics during the third quarter valued at $70,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently commented on HALO. TD Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday. Morgan Stanley reduced their price objective on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Benchmark raised their price objective on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, February 19th. Finally, Weiss Ratings upgraded shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. Seven research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $80.67.

Get Our Latest Report on Halozyme Therapeutics

Halozyme Therapeutics Trading Up 0.5%

HALO opened at $67.44 on Tuesday. The stock has a 50-day moving average of $65.65 and a 200 day moving average of $68.67. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81. Halozyme Therapeutics, Inc. has a 12 month low of $51.06 and a 12 month high of $82.22. The firm has a market cap of $8.00 billion, a P/E ratio of 24.26, a P/E/G ratio of 0.27 and a beta of 0.89.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last posted its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. The business had revenue of $376.71 million for the quarter, compared to analysts’ expectations of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The business’s revenue was up 42.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, research analysts forecast that Halozyme Therapeutics, Inc. will post 7.66 EPS for the current year.

Insider Activity

In other news, CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $69.19, for a total transaction of $691,900.00. Following the transaction, the chief executive officer owned 767,780 shares in the company, valued at approximately $53,122,698.20. This trade represents a 1.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the business’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $63.48, for a total transaction of $103,155.00. Following the completion of the sale, the director owned 38,498 shares of the company’s stock, valued at approximately $2,443,853.04. This represents a 4.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 120,482 shares of company stock valued at $8,200,842. 2.50% of the stock is currently owned by company insiders.

About Halozyme Therapeutics

(Free Report)

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.